Jupiter Topco LLC Acquires New Position in PROCEPT BioRobotics Corporation $PRCT

Posted by Stanley Muller on Aug 29th, 2026

Jupiter Topco LLC bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 1,103,404 shares of the company’s stock, valued at approximately $24,914,000. Jupiter Topco LLC owned 1.93% of PROCEPT BioRobotics at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PRCT. Caitong International Asset Management Co. Ltd lifted its holdings in shares of PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after buying an additional 746 shares during the period. Versant Capital Management Inc grew its holdings in PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock worth $27,000 after acquiring an additional 1,084 shares during the period. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics during the fourth quarter worth $40,000. US Bancorp DE raised its position in PROCEPT BioRobotics by 175.7% in the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after acquiring an additional 1,079 shares in the last quarter. Finally, Cache Advisors LLC purchased a new position in PROCEPT BioRobotics in the first quarter worth $42,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

Neutral Sentiment: Multiple law firms, including Kaplan Fox, Rosen Law Firm and Hagens Berman, announced or reiterated that a securities class action has been filed on behalf of investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors seeking to serve as lead plaintiff must act by September 22, 2026. Kaplan Fox class-action notice
Negative Sentiment: The complaint reportedly alleges that PROCEPT understated weakness in unit handpiece sales and failed to disclose elevated customer inventory, while using repeated late-quarter bulk discounts to pull demand forward. The allegations concern potential violations of federal securities laws and could increase litigation costs, reputational risk and investor uncertainty; they have not been proven in court. Hagens Berman PROCEPT investor alert
Negative Sentiment: The unusually high number of law-firm solicitations over the past two days keeps attention focused on the lawsuit and the company’s prior sales and inventory disclosures. Although the notices do not introduce a new financial result or regulatory action, continued headlines may weigh on sentiment and limit the stock’s recovery.

Analyst Upgrades and Downgrades

PRCT has been the topic of several research analyst reports. Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. UBS Group downgraded shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target for the company. in a report on Tuesday, July 28th. Jefferies Financial Group reiterated a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th. Finally, Robert W. Baird set a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, PROCEPT BioRobotics currently has an average rating of “Hold” and an average price target of $28.00.

View Our Latest Report on PRCT

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock opened at $20.83 on Friday. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $42.43. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The firm’s 50-day simple moving average is $20.32 and its 200 day simple moving average is $23.93. The firm has a market capitalization of $1.19 billion, a PE ratio of -10.74 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) earnings per share. On average, equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood purchased 23,900 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 1,000 shares of company stock valued at $28,480 in the last quarter. 4.00% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Company Profile

(Free Report)

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.